» Articles » PMID: 37629672

The Effect of Synbiotic Supplementation on Uremic Toxins, Oxidative Stress, and Inflammation in Hemodialysis Patients-Results of an Uncontrolled Prospective Single-Arm Study

Overview
Publisher MDPI
Specialty General Medicine
Date 2023 Aug 26
PMID 37629672
Authors
Affiliations
Soon will be listed here.
Abstract

: Numerous studies to date have shown that the development of dysbiotic gut microbiota is a characteristic finding in chronic kidney disease (CKD). A number of uremic toxins progressively accumulate in the course of CKD, some of them generated by the intestinal microbiome, such as indoxyl sulfate (IS) and p-cresyl sulfate (p-CS). They are found to be involved in the pathogenesis of certain complications of uremic syndrome, including low-grade chronic inflammation and oxidative stress. The aim of the present study is to research the serum concentration of IS and p-CS in end stage renal disease (ESRD) patients undergoing conventional hemodialysis, as well as to study the possibilities of influencing some markers of inflammation and oxidative stress after taking a synbiotic. : Thirty patients with end-stage renal disease (ESRD) undergoing hemodialysis treatment who were taking a synbiotic in the form of La-14 2 × 10 (CFU)/g and prebiotic fructooligosaccharides were included in the study. Serum levels of total IS, total p-CS, Interleukin-6 (IL-6), and Malondialdehyde (MDA) were measured at baseline and after 8 weeks. . The baseline values of the four investigated indicators in the patients were significantly higher-p-CS (29.26 ± 58.32 pg/mL), IS (212.89 ± 208.59 ng/mL), IL-6 (13.84 ± 2.02 pg/mL), and MDA (1430.33 ± 583.42 pg/mL), compared to the results obtained after 8 weeks of intake, as we found a significant decrease in the parameters compared to the baseline-p-CS (6.40 ± 0.79 pg/mL, = 0.041), IS (47.08 ± 3.24 ng/mL, < 0.001), IL-6 (9.14 ± 1.67 pg/mL, < 0.001), and MDA (1003.47 ± 518.37 pg/mL, < 0.001). : The current study found that the restoration of the intestinal microbiota in patients with CKD significantly decreases the level of certain uremic toxins. It is likely that this favorably affects certain aspects of CKD, such as persistent low-grade inflammation and oxidative stress.

Citing Articles

Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled Trial.

Trugilho L, Alvarenga L, Cardozo L, Paiva B, Brito J, Barboza I J Nutr Metab. 2025; 2025():8482883.

PMID: 39840146 PMC: 11745556. DOI: 10.1155/jnme/8482883.


Gut Microbiota in Patients Receiving Dialysis: A Review.

Lim X, Ooi L, Ding U, Wu H, Chinnadurai R Pathogens. 2024; 13(9).

PMID: 39338992 PMC: 11434973. DOI: 10.3390/pathogens13090801.


Exploring the gut microbiome: probiotics, prebiotics, synbiotics, and postbiotics as key players in human health and disease improvement.

Kim Y, Mills D Food Sci Biotechnol. 2024; 33(9):2065-2080.

PMID: 39130661 PMC: 11315840. DOI: 10.1007/s10068-024-01620-1.


Exploring the Preventive and Therapeutic Mechanisms of Probiotics in Chronic Kidney Disease through the Gut-Kidney Axis.

Huang H, Chen M J Agric Food Chem. 2024; 72(15):8347-8364.

PMID: 38571475 PMC: 11036402. DOI: 10.1021/acs.jafc.4c00263.


The Kidney-Gut Axis as a Novel Target for Nutritional Intervention to Counteract Chronic Kidney Disease Progression.

Cabala S, Ozgo M, Herosimczyk A Metabolites. 2024; 14(1).

PMID: 38276313 PMC: 10819792. DOI: 10.3390/metabo14010078.

References
1.
Gryp T, Vanholder R, Vaneechoutte M, Glorieux G . p-Cresyl Sulfate. Toxins (Basel). 2017; 9(2). PMC: 5331431. DOI: 10.3390/toxins9020052. View

2.
Sun J, Axelsson J, Machowska A, Heimburger O, Barany P, Lindholm B . Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD. Clin J Am Soc Nephrol. 2016; 11(7):1163-1172. PMC: 4934843. DOI: 10.2215/CJN.10441015. View

3.
Nangaku M, Mimura I, Yamaguchi J, Higashijima Y, Wada T, Tanaka T . Role of uremic toxins in erythropoiesis-stimulating agent resistance in chronic kidney disease and dialysis patients. J Ren Nutr. 2015; 25(2):160-3. DOI: 10.1053/j.jrn.2014.10.011. View

4.
Vaziri N, Wong J, Pahl M, Piceno Y, Yuan J, DeSantis T . Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2012; 83(2):308-15. DOI: 10.1038/ki.2012.345. View

5.
Gevers D, Knight R, Petrosino J, Huang K, McGuire A, Birren B . The Human Microbiome Project: a community resource for the healthy human microbiome. PLoS Biol. 2012; 10(8):e1001377. PMC: 3419203. DOI: 10.1371/journal.pbio.1001377. View